



World Organisation
for Animal Health



Substandard and Falsified Veterinary Products Workshop

4 - 6 March 2025. Dar es Salaam, Tanzania.




The
Fleming
Fund



Outline

- **GALVmed** at a glance
- Ongoing **Activities**
- **Better Regulation Project** and Role of WOAHA



PROTECTING LIVESTOCK IMPROVING HUMAN LIVES


GALVmed

Protecting Livestock - Improving Human Lives

galvmed.org



Fastest growing, highest-value agricultural subsector globally.



70% of the rural poor depend on livestock for income (FAO).



Greater demand for animal-derived protein.



Growing business interest in sub-Saharan Africa and South Asia.



Help to **address stunting** in children.



Prospects for **rural employment, women and youth**.



Over 20% of animal production losses are linked to infectious animal diseases.



Increased need for **greater efficiency** in livestock production.



Vaccines prevent and manage **antimicrobial resistance**.



Better **use and access** of veterinary medicine can improve **One Health**.





Our vision is...

transformational improvement in the wellbeing and **economic** progression of **smallholder** livestock farmers.

Our mission is...

to contribute to the transformation of smallholder farmers' lives by:

Understanding the constraints to animal health and how to overcome them.

Engaging the animal health industry.

Ensuring **awareness, availability & adoption** of effective animal health interventions.

? WHAT

- An Animal Health product and business development.
- International non for-profit organization.




? WHY

- Transformational improvement in the wellbeing and economic progression of small-scale livestock producers (SSPs).
- Improve access to veterinary products SSPs in sub-Saharan Africa and the Indian subcontinent.



? HOW


- Understanding barriers to entry to animal health and how to overcome them.
- Engaging animal health industry stakeholders.
- Awareness, availability & adoption of effective animal health interventions.





1. Research & Development: Facilitating partnerships with universities, research institutes, and the private sector to develop high impact health interventions.

2. Commercial Development: Working with private sector partners who are willing to develop sustainable and scalable business models that focus on serving SSP segments.



Progress at scale must happen via **markets.**

3. Favorable Policy **Trained Frontline Vets** **Robust Markets**



4. Data & Monitoring



3. Enabling Environment: Working with advocacy groups, regulators, the animal health industry and government bodies to ease barriers in the regulatory and market environment.

4. Monitoring & Evaluation: Delivering pragmatic data and information from the SSP field which quantifies impact and informs strategy and operational plans.



DISEASE PRIORITIES

- Infectious diseases that severely constrain small-scale livestock production (poultry, sheep, goat, cattle and swine).



COUNTRIES

- We prioritize a set of 3 Tier 1 countries. (Kenya, Tanzania and Nigeria).
- Support commercial partners taking a broader and more regional approach.





BY 2030 GALVMED WILL HAVE ACHIEVED:

1. Through R&D activities
A significantly enhanced portfolio of SSP products and technologies.



2. Through CD activities
Transformed supply and uptake of key animal health products for the SSP segment.



3. Through R&D, CD, EE activities
Tangible investment and engagement in the SSP segment by the animal health industry.




Overarching Objective: significantly improved livestock health and productivity → lives & livelihoods of millions of SSPs materially improved in terms of economic benefit.

**OVERARCHING OBJECTIVE:
HEADLINE OBJECTIVES BY 2030**

- 1**
 - 24 New products.
 - 3 New technologies.
 - 1 Product dev. Platform.
 - 3 Manufacturers facilitated.
- 2**
 - 200 product registrations.
 - 15 manufacturers engaged in SSP distribution platforms.
- 3**
 - 60% availability of 'necessary' product inventory.
 - 80%, 50% adoption of available 'essential'/'advisory' products.
 - 10 Million SSP customers served with key products and services.
 - \$73 average economic benefit per SSP customer.

\$730 MILLION SSP WEALTH CREATED



SOME OF GALVMED's ACHIEVEMENTS



**~6.2 MILLION
CUMULATIVE
ANNUAL
CUSTOMERS**

over the period
2014 – 2023

**2.9 BILLION
DOSES**

of livestock vaccines,
therapeutics and other
animal health products
sold to SSP customers
across Africa and South
Asia from 2014 – 2023



**~\$126
MILLION**

in poultry deaths averted
between 2014 and 2023

**38.7 MILLION
LIVESTOCK
DEATHS
AVERTED**

from 2014 – 2023

16 PRODUCTS

taken to full
development since 2010

17 PRODUCTS

registered to date under
the Mutual Recognition
Procedure (MRP)



VACCINES DEVELOPED

**Cattle combo.
CBPP-LSD
BIVALENT
VACCINE**

with RVF
co-administration.
Needed throughout Africa.

**Sheep-goat combo.
CCPP-PPR-SGP
TRIVALENT
VACCINE**

Needed throughout
Africa.

**Marked PPR.
FOR FINAL
DISEASE
CONTROL
SCENARIOS**

Essential for the Global
Eradication of PPR.

**Poultry combo.
ND-IB
MULTIVALENT
VACCINE**

Needed throughout
Africa.

**Marked PPR.
NOVEL
TECHNOLOGY**

Vaccine stabilization
formulation. Enables cheaper
vaccine production & easier
field use for vaccines.



Improving Access to Quality Veterinary Products via Better Regulation

- Funded by the **Gates Foundation**
- PI, Dr **Lois Muraguri**
- Led by **GALVmed** with **UK-VMD, WOAHA and EAC** as partners
- Project start date, 1st June 2024, **36 months funding**
- Total **budget** \$4,958,655

Core themes and milestones

- 1. SSA Governance Structure: decision made on need and form of governance structure (31st May 2025); agreement from potential host (31st May 2026); and funding strategy in place (31st May 2027)**
- 2. SA tool: decision by WOAHA Members to support global adoption of the SA tool (31st May 2027)**
3. EAC MRP: systems in place that can monitor EAC MRP performance and clear pathway to sustainability (31st May 2025); additional countries adopted into MRP (31st May 2027)

Outputs and outcomes

WP1: Project management and oversight.

- Output: **12 months** - Project Steering Committee structure established and operational including representation from SSA.
- Output: **24 months** - Successful delivery of WP2, 3, 4 outputs on time and on budget.
- Output: **36 months** - Successful delivery of WP2, 3, 4 outputs on time and on budget.

Outcomes: Clear project governance and oversight mechanisms embedded to ensure the progress of the project is robustly reviewed to best achieve the goals of the investment.

Outputs and outcomes

WP2: Evaluating the potential for a SSA Governance Structure to Improve Access to High Quality Veterinary Medicines Through Better Regulation.

- Output: **12 months** – Consultants engaged to conduct scoping work including potential representation on the Governance structure through consultation with stakeholders.
- Output: **24 months** – Potential hosts for Governance structure identified and shortlist compiled with partners keen to lead and drive improvements to access for high quality veterinary medicines across SSA.
- Output: **36 months** – Funding strategy established for longer term support for Secretariat for new Governance structure, with clear leadership from countries in SSA.

Outcomes: To have completed scoping work and consulted with stakeholders to establish the pull from EAC countries for improved access to high quality veterinary medicines through better regulation, with a host identified, appropriate member representation from different regions and a funding strategy to support the secretariat.

Outputs and outcomes

WP3: Further developing the Self-Assessment Tool and securing its uptake at regional and global level.

- Output: **12 months** – Resource within WOAHA in place, training from VMD and review of work to date complete. Three pilot studies initiated (two in person, one remote) with plan for pilots from different parts of the world to provide data to support global adoption. Self-assessment tool piloted by at least two NRAs in EAC region.
- Output: **24 months** – Assessment by WOAHA members of self-assessment tool completed. VMD develop and review initial training tools to support broader scope of pilot studies. Additional pilot studies underway including at least one region outside of SSA.
- Output: **36 months** – Decision by WOAHA as to whether it will adopt the Tool for global deployment among its members. Additional pilot studies undertaken by the VMD in collaboration with WOAHA and availability of the Tool in additional languages (if required to maximize accessibility). VMD to have explored alternative host for the tool as a backup. Report on diagnostics regulatory harmonization activities undertaken by WOAHA as part of this project.

Outcomes: Commitment for global adoption of self-assessment tool within WOAHA or alternate process identified. Tool refined and updated and ready for global deployment.

Outputs and outcomes

WP4: Maturity & Sustainability of EAC MRP.

- Output: **12 months** – Completion of sustainability review to identify existing gaps in EAC MRP, with costing modelling completed and business modelling initiated to support self-sustainability. Systems in place (e.g., Tableau Dashboard) to monitor how well EAC MRP is functioning.
- Output: **24 months** – Plan for sustainability mapped out with business modelling complete.
- Output: **36 months** – Identified gaps addressed, adoption of MRP by additional countries, plan for sustainability initiated and any areas on the Dashboard updated. Reliance guidelines in place for mutually accepting regulatory approvals.

Outcomes: Demonstration that MRP can be rolled out across a region within SSA, with broad adoption and plans for a sustainable business model driven by regional stakeholders. Systems in place to monitor performance of EAC MRP (e.g., Tableau Dashboard).

Vision by 2030

Looking beyond this project, the vision is that by 2030:

- A sustainable Governance structure for SSA will be in place with clear leadership from countries in the region.
- Capacity building funding will have been secured to address gaps identified by the self-assessment tool in at least two countries.
- Two additional EAC countries will be participating as Concerned Countries in the MRP.


Pathway towards 2030

Systems in place (e.g., Tableau Dashboard) to monitor how well EAC MRP is functioning. ¹

Host for SSA Governance structure and Secretariat identified. ²
Assessment by WOH members of SA tool. ³

SA tool moves to final host. ³

Two additional EAC countries participating as Concerned Countries in MRP. ¹
Sustainable Governance structure in place with clear leadership from within SSA. ²
Capacity building funding secured to address gaps identified by SA tool in at least two countries. ^{1,3}



2024

2025

2026

2027

2028

2029

2030

EAC Sustainability plan initiated.
SA tool piloted by at least two NRA in EAC region.

Reliance guidelines in place for mutually accepting regulatory approvals.
Funding strategy in place for SSA Governance structure.
Decision by WOH members to adopt the SA tool.

NRA lighthouse in EAC region.
Structures in Tier 2 EAC countries that enable products to be registered.

If you want to know more
about us, please visit:
www.galvmed.org



Protecting Livestock - Improving Human Lives



THANK YOU